ArticlePloS one2016
Interleukin 6 Accelerates Mortality by Promoting the Progression of the Systemic Lupus Erythematosus-Like Disease of BXSB.Yaa Mice.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- The effects of curcumin supplementation on inflammatory markers in systemic lupus erythematosus patients: a randomized placebo-controlled trial.European journal of nutrition · 2024Trial
- Proinflammatory keratinocytes drive a novel mouse model of autoimmunity with systemic and cutaneous lupus erythematosus.Immunity & inflammation · 2026Article
- Glucose oxidation-dependent survival of activated B cells provides a putative novel therapeutic target for lupus treatment.iScience · 2023Article
- Dysregulated IFN-γ signals promote autoimmunity in STAT1 gain-of-function syndrome.Science translational medicine · 2023Article
- Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model.Lupus science & medicine · 2021Article
- BANK1 interacts with TRAF6 and MyD88 in innate immune signaling in B cells.Cellular & molecular immunology · 2020Article
- Abrogated AID Function Prolongs Survival and Diminishes Renal Pathology in the BXSB Mouse Model of Systemic Lupus Erythematosus.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- TLR9 activation induces aberrant IgA glycosylation via APRIL- and IL-6-mediated pathways in IgA nephropathy.Kidney international · 2020Article
- Performance of cytokine models in predicting SLE activity.Arthritis research & therapy · 2019Article
- Non-Antibody-Secreting Functions of B Cells and Their Contribution to Autoimmune Disease.Annual review of cell and developmental biology · 2019Review
- Dysregulation of T Follicular Helper Cells in Lupus.Journal of immunology (Baltimore, Md. : 1950) · 2019Review
- TLR7-Mediated Lupus Nephritis Is Independent of Type I IFN Signaling.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- TGF-β-Induced CD8Frontiers in immunology · 2018Article
- Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.Experimental and therapeutic medicine · 2018Article
- B cell-derived IL-6 initiates spontaneous germinal center formation during systemic autoimmunity.The Journal of experimental medicine · 2017Article
- Altered B cell signalling in autoimmunity.Nature reviews. Immunology · 2017Review
- Targeting CD22 with the monoclonal antibody epratuzumab modulates human B-cell maturation and cytokine production in response to Toll-like receptor 7 (TLR7) and B-cell receptor (BCR) signaling.Arthritis research & therapy · 2017Article
- Pathways leading to an immunological disease: systemic lupus erythematosus.Rheumatology (Oxford, England) · 2017Review
- New Treatments for Systemic Lupus Erythematosus on the Horizon: Targeting Plasmacytoid Dendritic Cells to Inhibit Cytokine Production.Journal of clinical & cellular immunology · 2017Article
- Transgenic mouse model of IgMBlood cancer journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 2 countries.
Funding
Abstract
IL6 is a multifunctional cytokine that drives terminal B cell differentiation and secretion of immunoglobulins. IL6 also cooperates with IL21 to promote differentiation of CD4+ T follicular helper cells (TFH). Elevated serum levels of IL6 correlate with disease flares in patients with systemic lupus erythematosus (SLE). We previously reported that IL21 produced by TFH plays a critical role in the development of the SLE-like disease of BXSB.Yaa mice. To examine the possible contributions of IL6 to disease, we compared disease parameters in IL6-deficient and IL6-competent BXSB.Yaa mice. We report that survival of IL6-deficient BXSB.Yaa mice was significantly prolonged in association with significant reductions in a variety of autoimmune manifestations. Moreover, B cells stimulated by co-engagement of TLR7 and B cell receptor (BCR) produced high levels of IL6 that was further augmented by stimulation with Type I interferon (IFN1). Importantly, the frequencies of TFH and serum levels of IL21 were significantly reduced in IL6-deficient mice. These findings suggest that high-level production of IL6 by B cells induced by integrated signaling from the IFN1 receptor, TLR7 and BCR promotes the differentiation of IL21-secreting TFH in a signaling sequence that drives the lethal autoimmune disease of BXSB.Yaa mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.